Inhibikase Therapeutics director Bellini gets $2m in stock via Investing.com
Roberto Bellini, director at Inhibikase Therapeutics Inc. (NASDAQ:IKT), purchased 1,460,000 shares of the company's common stock on October 21, 2024. The shares were acquired at a price of $1.37 each, amounting to a total transaction value of approximately $2,000,20.2 . The acquisition was made through BSQUARED CAPITAL INC, of which Bellini is a shareholder and executive.
In addition to the stock purchase, Bellini also received stock options for 60,000 shares with an exercise price of $2.22 per share. The options vest 50% on each of the first two anniversaries of October 21, 2024, and will expire on October 21, 2034.
In other recent news, Inhibikase Therapeutics had its stock target revised by HC Wainwright to $5.00 from $15.00. Despite this, the company continues to recommend Inhibikase as a Buy. The settlement follows Inhibikase's announcement of a private placement aimed at raising approximately $110 million. The financing involves the sale of common stock and warrants, with the proceeds planned to fund the Phase 2b trial of IkT-001Pro for pulmonary arterial hypertension (PAH) and other business purposes.
Inhibikase recently reported a net loss of $5.0 million in the second quarter but managed to raise $4 million in May, extending its cash flow until December 2024. HC Wainwright revised its full-year 2024 earnings per share (EPS) forecast for Inhibikase to ($2.75), down from the previous estimate. The company also completed enrollment in its Phase 2 study of risvodetinib for Parkinson's disease, with peak data expected soon.
The company's latest developments include an Investigational New Drug (IND) application for Pro's imatinib mesylate PAH drug, with clinical development set to begin later this year. Inhibikase is also exploring financing options for the risvo Multiple System Atrophy program and developing diagnostic tools. These latest developments demonstrate Inhibikase's continued commitment to advancing its clinical trials and addressing unmet medical needs.
InvestingPro Insights
Roberto Bellini's largest investment in Inhibikase Therapeutics Inc. (NASDAQ:IKT) comes at a time when the company's stock has shown impressive performance. According to InvestingPro data, IKT delivered a strong return of 184.54% last year, with a whopping 107.69% return in the last month alone. This latest attack is consistent with Bellini's stance on the company's prospects for sustainability.
However, potential investors should be aware that IKT is currently trading at a high dividend yield, as highlighted in one of InvestingPro's tips. This suggests that the market may have an expected rate of growth. Another relevant InvestingPro Tip indicates that the company is quickly burning through cash, which may be a concern given its lack of profitability over the past twelve months.
Despite these challenges, IKT has more cash than debt on its balance sheet, providing some financial flexibility. This can be important as the company navigates its growth phase in the competitive biotech industry.
For those thinking of following Bellini's lead, it is important to note that InvestingPro offers 14 additional IKT advisories, providing a comprehensive analysis of the company's financial health and market conditions. This information can be useful in making informed investment decisions in this volatile sector.
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
